In 16 Asian women, picosecond and Q-switched Nd:YAG treatments produced improvement without a significant difference in six-month recurrence

Choosing a newer picosecond laser over a Q-switched system may not automatically deliver better melasma control. A randomised, double-blind split-face trial published in June 2026 compared two 1064-nm Nd:YAG approaches in 16 Asian women with Fitzpatrick skin types III–IV and found no statistically significant difference in the principal melasma outcomes between treatments.

Participants received three sessions at four-week intervals, with one half of the face treated with a picosecond system and the other with a Q-switched device. Researchers assessed hemi-modified Melasma Area and Severity Index scores and global improvement during follow-up, including six months after the final treatment. Both sides improved over time, but neither modality showed a clear advantage in the severity score or global improvement.

The picosecond-treated side did have significantly lower pain scores after the first session. That may matter when discussing patient tolerance, although the finding does not establish an overall superiority in effectiveness or long-term comfort. The investigators also found no significant difference between treatments in recurrence at six months.
The study addresses a familiar clinical dilemma. Melasma is often chronic and relapsing, and device innovation can be attractive when topical treatment alone produces incomplete or short-lived improvement. Yet clinicians must balance the potential for pigment improvement against rebound, post-inflammatory hyperpigmentation, and the need for long-term photoprotection and maintenance. Treatment technology is only one part of that plan.

An important strength of the study is its split-face design: each participant acted as her own comparator, reducing some patient-level variation. However, the sample was small, limited to women with phototypes III–IV, and the study was conducted under specified treatment settings. It cannot establish that the same results will apply to every melasma subtype, skin tone, device protocol or combination regimen.

For aesthetic physicians, the practical message is not that the two technologies are interchangeable in all circumstances. Treatment choice should be grounded in a patient’s pigment history, phototype, tolerance, risk profile, and realistic expectations, rather than the assumption that shorter pulses necessarily mean better results. Larger trials with longer follow-up are needed to determine whether particular subgroups benefit more from one approach.